Intellia Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

NTLA$12.11+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTELLIA THERAPEUTICS, INC.
By:	/s/ John M. Leonard
	John M. Leonard, M.D.
	President and Chief Executive Officer

Dated: February 26, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.

Muna Bhanji
Name	Title	Date
/s/ John M. Leonard	President, Chief Executive Officer and Director	February 26, 2026
John M. Leonard, M.D.	(Principal Executive Officer)
/s/ Edward J. Dulac III	Executive Vice President, Chief Financial Officer	February 26, 2026
Edward J. Dulac III	(Principal Financial Officer)
/s/ Michael P. Dube	Vice President, Chief Accounting Officer	February 26, 2026
Michael P. Dube	(Principal Accounting Officer)
/s/ Muna Bhanji	Director	February 26, 2026
/s/ Bill Chase	Director	February 26, 2026
Bill Chase
/s/ Fred Cohen	Director	February 26, 2026
Fred Cohen, M.D.
/s/ Brian Goff	Director	February 26, 2026
Brian Goff
/s/ Jesse Goodman	Director	February 26, 2026
Jesse Goodman, M.D.
/s/ Georgia Keresty	Director	February 26, 2026
Georgia Keresty

Frank Verwiel, M.D.
/s/ Frank Verwiel	Director	February 26, 2026

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.